Imagine a future where cutting-edge cancer treatments are developed and tested right on a university campus, offering new hope to patients. That future is here, and it's happening at the University of Missouri. In a groundbreaking move, the University of Missouri has launched its first on-campus radiopharmaceutical clinical trial, marking a significant milestone in the fight against cancer. But here's where it gets even more exciting: this trial is not just about treating cancer; it's about showcasing the university's unparalleled research capabilities, from development to human testing, all under one roof.
The School of Medicine and MU Health Care, in collaboration with ABK Biomedical, have enrolled their first patient in a clinical trial using Eye90 microspheres®, a revolutionary therapy manufactured on campus at the university's research reactor. Treatment began on February 9 at MU Health Care's Ellis Fischel Cancer Center, signaling a major leap forward in Mizzou's ability to conduct radiopharmaceutical clinical trials, supported by the NextGen Precision Health initiative. And this is the part most people miss: Mizzou's unique position as home to the nation's largest university research reactor and state-of-the-art facilities in veterinary medicine and precision health allows for unprecedented collaboration between academia and industry, accelerating the journey from lab to patient.
But what makes this trial truly stand out? Eye90 microspheres are no ordinary treatment. These radiopaque glass beads, embedded with the radioisotope yttrium-90 (Y-90), are designed to target unresectable liver tumors with precision, minimizing damage to healthy tissue. The University of Missouri Research Reactor (MURR) is the sole domestic source of Y-90, making Mizzou a critical player in the production of this life-saving therapy. This raises a thought-provoking question: Could Mizzou's unique resources and expertise position it as a global leader in nuclear medicine and cancer treatment?
Ryan Davis, associate professor of clinical radiology and on-site study coordinator, emphasizes the trial's importance: 'This study not only provides early access to innovative therapies for our patients but also solidifies our leadership in translational research. Targeted radiotherapy is becoming increasingly vital in treating metastatic tumors, and we're proud to be at the forefront of this movement.'
However, the story doesn’t end here. Mizzou's involvement in radiopharmaceuticals dates back to the 1980s, when Delbert Day and Gary Ehrhardt pioneered the development of TheraSphere, the first microsphere treatment. TheraSphere received full FDA approval in 2021, and MURR remains the only U.S. producer. For the Eye90 microspheres, ABK Biomedical partnered with MURR to irradiate and process the microspheres on-site, ensuring a reliable supply for preclinical and clinical trials. Mizzou researchers, led by Jeffrey Bryan, conducted critical effectiveness and safety studies, including trials in dogs with hepatocellular carcinoma, paving the way for human trials.
Looking ahead, the Mizzou clinical trial is part of a larger effort to evaluate Eye90's safety and efficacy in patients with unresectable liver tumors. The study involves a single administration followed by a year of monitoring, focusing on tumor response and quality of life. ABK Biomedical has already initiated similar studies internationally, with the first patient treated in New Zealand. The goal is to gather robust data for regulatory approvals and wider clinical adoption.
But here's the controversial part: As Mizzou continues to push the boundaries of cancer research, it raises questions about the accessibility of such advanced treatments. Will these innovations remain confined to well-resourced institutions, or can they be scaled to benefit patients globally? We’d love to hear your thoughts in the comments.
Mizzou and Ellis Fischel are committed to advancing patient care through cutting-edge research and collaboration, offering new hope to cancer patients everywhere. This trial is not just a scientific achievement; it's a testament to what's possible when academia, industry, and healthcare unite for a common cause. What do you think? Is Mizzou's approach the future of cancer research, or is there more to be done? Share your perspective below!
